Diatrizoate

Evidence Level: L5

Predicted Indications: 1

Diatrizoate

Pharmacist Assessment Report

Diatrizoate: From an Unspecified Original Indication to Rheumatoid Arthritis

One-Sentence Summary

Diatrizoate is an iodinated radiographic contrast agent. The data compiled for this report contain no approved indication text for it in Canada. The TxGNN model predicts it may be effective for rheumatoid arthritis, but there are 0 clinical trials and only 1 publication, and that publication uses diatrizoate as a laboratory reagent rather than as a treatment. The evidence is model prediction only.

Quick Overview

Item	Content
Original Indication	Not available (no approved indication text in the licence record)
Predicted New Indication	Rheumatoid arthritis
TxGNN Prediction Score	0.9902
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Number of approvals	1 licence (single-ingredient)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Diatrizoate is an iodinated, high-osmolar contrast agent. It has no known immunomodulatory or anti-inflammatory activity, and no therapeutic mechanism links it to rheumatoid arthritis.

The high TxGNN score (0.9902) is a model output only. Neither clinical nor mechanistic evidence supports it. The one linked publication (PMID 6491310, 1984) describes separating blood cells from normal and rheumatoid arthritis patients by density-gradient centrifugation. The medium used was Ficoll-Hypaque, which contains diatrizoate salts. Here diatrizoate is a laboratory separation reagent and was not given to patients. The prediction may reflect this co-occurrence in the literature rather than a real treatment effect, so it should be treated with caution.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
6491310	1984	Laboratory/methodological study	Journal of Immunological Methods	Ficoll-Hypaque and Ficoll-Nycodenz media (diatrizoate-containing) were compared for centrifugal separation of leucocytes from normal and rheumatoid arthritis blood. This is an in vitro method study and gives no evidence of therapeutic effect.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02228564	GASTROGRAFIN	Not stated	Not stated

Safety Considerations

Drug Interactions: The interaction database lists 100 interacting drugs for diatrizoate, and the 20 examined here are mostly rated Major. They include:
- Metformin
- Amphotericin B (including the lipid complex, cholesteryl sulfate and liposomal forms)
- Aminoglycosides and related antibiotics (kanamycin, neomycin, streptomycin, polymyxin B, vancomycin)
- Aminosalicylates (mesalazine, balsalazide, olsalazine, sulfasalazine)
- Ketorolac
- Acyclovir
Moderate-level interactions include mannitol, acebutolol, acetazolamide and nifedipine.

Please refer to the package insert for warnings and contraindications, as these were not available in the data compiled for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a model score alone. The only linked publication uses diatrizoate as a cell-separation reagent, and there is no plausible therapeutic mechanism and no clinical trial for rheumatoid arthritis. The evidence level is L5.

To proceed, the following is needed:

Mechanism of action data and a credible biological rationale for rheumatoid arthritis
Health Canada product monograph warnings, contraindications and approved indication text
Preclinical or clinical studies that test diatrizoate itself in rheumatoid arthritis
Confirmation of route compatibility, since the licensed product is a contrast agent and not a therapeutic one
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.